Heron Therapeutics, Inc. /De/ filed a Form 8-K with the U.S. Securities and Exchange Commission (SEC) at 12:40 UTC on Monday, 9 November 2026. The filing reports Item 1.01, Entry into a Material Definitive Agreement.
A Form 8-K is the report U.S. public companies file to tell investors about significant events between their regular quarterly and annual reports. Each item in the form covers one type of event.
The accompanying press release (Exhibit 99.1) opens: CorMedix Therapeutics to Acquire Substantially All Assets of Heron Therapeutics, Expanding Its Portfolio of Products Used in Institutional Settings of Care
The filing also lists Item 3.03, as listed in the filing; Item 7.01, Regulation FD Disclosure; Item 9.01, Financial Statements and Exhibits.
Source: U.S. Securities and Exchange Commission (EDGAR) filing